Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer
Guarneri V, Fasching P, Fernandez Abad M, Garcia-Saenz A, Schneeweiss A, Colleoni M, Petru E, Costigan TM, Caldwell CW, Barriga S, Hurvitz S, Slamon D (2017)
Publication Type: Conference contribution
Publication year: 2017
Journal
Book Volume: 28
Pages Range: 19-19
Authors with CRIS profile
Involved external institutions
Hospital Clínico San Carlos
Spain (ES)
University of Padua / Universita degli Studi di Padova
Italy (IT)
Eli Lilly and Company
United States (USA) (US)
Hospital Universitario Ramón y Cajal
Spain (ES)
Deutsches Krebsforschungszentrum (DKFZ)
Germany (DE)
University of California Los Angeles (UCLA)
United States (USA) (US)
European Institute of Oncology / Istituto Europeo di Oncologia (IEO)
Italy (IT)
Spain (ES)
University of Padua / Universita degli Studi di Padova
Italy (IT)
Eli Lilly and Company
United States (USA) (US)
Hospital Universitario Ramón y Cajal
Spain (ES)
Deutsches Krebsforschungszentrum (DKFZ)
Germany (DE)
University of California Los Angeles (UCLA)
United States (USA) (US)
European Institute of Oncology / Istituto Europeo di Oncologia (IEO)
Italy (IT)
How to cite
APA:
Guarneri, V., Fasching, P., Fernandez Abad, M., Garcia-Saenz, A., Schneeweiss, A., Colleoni, M.,... Slamon, D. (2017). Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer. (pp. 19-19).
MLA:
Guarneri, V., et al. "Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer." 2017. 19-19.
BibTeX: Download